GHRP-2 vs Hexarelin.

GHRP-2 (growth hormone-releasing peptide-2; international nonproprietary name pralmorelin; development codes KP-102/GPA-748) is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. It belongs to the "classical" growth hormone secretagogue (GHS) family pioneered by Cyril Bowers in the 1980s and is a synthetic agonist of the ghrelin receptor. Unlike GHRH, it is structurally unrelated to any hypothalamic releasing hormone and instead mimics the endogenous gut peptide ghrelin.

Hexarelin (examorelin) is a synthetic hexapeptide growth hormone secretagogue (GHS), structurally derived from the GHRP-6 family of growth hormone-releasing peptides. It is an investigational compound that was studied in the 1990s and 2000s as a potential agent for probing and stimulating growth hormone secretion and, separately, for direct effects on the heart. It is not an approved drug.

GHRP-2 binds and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same Gq/11-coupled receptor targeted by ghrelin, expressed on anterior-pituitary somatotrophs and in the hypothalamus (including the arcuate nucleus). Receptor activation drives phospholipase C signaling, IP3/DAG generation, and intracellular calcium release, evoking pulsatile GH secretion. Because it acts through a pathway distinct from (and synergistic with) GHRH, GHRP-2 and GHRH together produce a markedly larger GH pulse than either alone. Its action on hypothalamic ghrelin-receptor circuits also explains its orexigenic (appetite-stimulating) effect and a degree of off-target activation of the corticotroph and lactotroph axes.

Hexarelin acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same pituitary/hypothalamic receptor activated by the natural hormone ghrelin. Receptor binding engages Gq/11-phospholipase C signaling, mobilizing intracellular calcium in pituitary somatotrophs and triggering pulsatile growth hormone release; this pathway is distinct from and synergistic with GHRH, and also opposes somatostatin tone. Hexarelin additionally binds CD36, a scavenger receptor expressed in cardiac and vascular tissue, which is the proposed basis for GH-independent cardiovascular effects observed in animal models. Because it is a non-selective secretagogue, it also stimulates ACTH/cortisol and prolactin release to a greater degree than more selective agents.

Human pharmacology is well characterized for acute, single-dose use: controlled studies show GHRP-2 reliably triggers a robust GH pulse, and in healthy men it increased subjective hunger and food intake, confirming it behaves as a ghrelin mimetic (Laferrère et al., JCEM 2005). On the strength of acute diagnostic data it is approved in Japan as a single-dose GH-deficiency provocation test, where the GH response separates GH-sufficient from GH-deficient subjects. Critically, the long-term therapeutic program failed: development for treating GH-deficient children/pituitary dwarfism reached Phase II but was not brought to market, in part because the GH response to GHRP-2 is blunted in people with GH deficiency relative to healthy individuals. There are essentially no rigorous long-term human trials demonstrating benefit for body composition, muscle, anti-aging, or performance. Claims in those areas rest on mechanism and short-term hormone changes, not proven clinical outcomes.

Human data exist but are limited to small, short-term, acute physiology studies rather than outcome trials. Acute intravenous hexarelin reliably raised serum growth hormone in healthy volunteers and was compared head-to-head with GH in a controlled human study (Imbimbo/Ghigo group, J Endocrinol Invest 1999, PMID 10342360). Separate small studies reported short-lasting increases in left ventricular ejection fraction and cardiac output in normal subjects, GH-deficient patients, and dilated-cardiomyopathy patients, effects that appeared GH-independent (Bisi/Broglio et al., Endocrine 2001, PMID 11322491). A chronic-administration study found that GH responses desensitized over weeks and characterized effects on the pituitary-adrenal axis and prolactin (Clin Endocrinol 1999, PMID 10341859). Most cardioprotection evidence (CD36-mediated ischemia/reperfusion protection, IL-1 signaling) is preclinical and rodent-based (e.g., Int Heart J 2017, PMID 28321024; review J Geriatr Cardiol 2014, PMID 25278975); none of this advanced to a successful human cardiac outcome trial, and clinical development was discontinued.

Documented acute effects in human studies include off-target stimulation of ACTH and cortisol and a transient rise in prolactin, a feature that distinguishes GHRP-2 from the more selective secretagogue ipamorelin (Arvat et al., Peptides 1997). As a ghrelin-receptor agonist it predictably stimulates appetite, and sustained GH/IGF-1 elevation carries the theoretical risks associated with the GH axis (insulin resistance, fluid retention, joint discomfort). The fundamental safety gap is that GHRP-2 has been studied chiefly as a one-time diagnostic agent; the consequences of repeated or chronic non-clinical use, including effects on the HPA axis, glucose metabolism, and any proliferative risk from prolonged IGF-1 elevation, have not been established in controlled long-term human trials. Material sold for "research" use is unregulated and may differ in identity, purity, or sterility from pharmaceutical-grade product.

Documented effects in human studies include hexarelin's lack of GH selectivity: it raises cortisol, ACTH, and prolactin alongside growth hormone, so it does not produce a clean GH signal. A well-described limitation is rapid tachyphylaxis/desensitization, with attenuated GH responses on repeated or continuous dosing demonstrated both in vitro (second-messenger level) and over weeks of human administration. Long-term safety in humans is essentially unknown because no large or extended trials were completed; chronic GHS-driven IGF-1 elevation raises theoretical concerns common to this class (fluid retention, insulin sensitivity changes, and the general caution that growth-promoting signaling could be undesirable in the setting of malignancy), but these are not established for hexarelin specifically. There is no established safety profile for non-clinical/self-administered use.

Approved in Japan (marketed by Kaken Pharmaceutical as GHRP Kaken 100) solely as a single-dose diagnostic agent for assessing growth hormone deficiency, and only for diagnosis, not therapy. It is one of very few growth hormone secretagogues approved anywhere: macimorelin (Macrilen) was approved by the FDA in 2017, also as a diagnostic, and anamorelin (Adlumiz) was approved in Japan in 2021 for cancer cachexia. It is not FDA-approved for any indication; in the United States and most jurisdictions it is investigational/research-use-only, and it is prohibited in sport under the WADA Prohibited List (S2, growth hormone secretagogues).

Hexarelin is investigational and has never received FDA or EMA marketing approval; its clinical development was discontinued. It is prohibited in sport at all times by WADA as a growth hormone secretagogue / GH-releasing peptide under category S2 of the Prohibited List, and it is generally sold only as a research-use-only chemical.